ESPE Abstracts

Purpose: The aim of this study is to investigate the influence of body mass index (BMI) on therapeutic effect in prepubertal children with idiopathic growth hormone deficiency (IGHD).

Methods: We conducted a retrospective study by chart review in a single center. A total of 138 patients (male n=90, female n=48) with idiopathic growth hormone deficiency who were was treated growth hormone for at least 2 years from January 2010 to May 2019 were analyzed.

Results: Among the 138 patients, 128 were normal weight (BMI<85th percentile) and 10 were overweight (95th>BMI≥85th percentile) and obese (BMI≥95th percentile). At the start of growth hormone treatment, birth weight (P=0.020), Weight SDS (P <0.001), BMI (P =0.003), and BMI SDS (P <0.001) were higher in the overweight and obese patient groups than in the normal group. During 2 years of growth hormone treatment, height SDS in normal weight patients increased from -2.64 ± 0.49 to -1.22 ± 0.60, and height SDS in overweight and obese patients increased from -2.58 ± 0.40 to -0.96 ± 0.78 in patients. The height gain for 2 years in overweight and obese group was higher than in normal weight group (P =0.024). In multiple regression analysis, BMI SDS was positively association with growth velocity (P =0.001) and the gain in height SDS (P <0.001).

Conclusion: BMI SDS was positively related with growth velocity and the gain in height SDS during 2 years of growth hormone treatment in IGHD patients. Growth hormone treatment had a better therapeutic effect in obese and overweight IGHD patients.